MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Ann Oncol' source. Sat, 20 Mar 2010 13:49:36 +0100 http://www.medworm.com/index.php?rid=3383361&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20237004%26dopt%3DAbstract CONCLUSIONS: RECIST may not be an optimal indicator of clinical benefit in immunotherapy trials. This article discusses alternative clinical trial designs and end points that may be more relevant for immunotherapy trials and may offer more effective prediction of survival in pivotal phase III studies. PMID: 20237004 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3383361 Wed, 17 Mar 2010 00:00:00 +0100 3383361 http://www.medworm.com/index.php?rid=3383363&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20233744%26dopt%3DAbstract CONCLUSIONS: In conclusion, a short 3-day course of palifermin may be able to reduce the toxicity of HDT and ASCT in patients with MM. Patients with impaired renal function at the time of HDT need additional strategies to further reduce the incidence of severe mucositis. PMID: 20233744 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3383363 Tue, 16 Mar 2010 00:00:00 +0100 3383363 http://www.medworm.com/index.php?rid=3383362&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20233745%26dopt%3DAbstract CONCLUSION: Bevacizumab combined with first-line chemotherapy may modify the predictive value of CTC during treatment possibly due to impaired tumor cells intravasation through vessels endothelium. Variations in CEC levels appear to be a promising early surrogate marker of TtP under antiangiogenic treatment. PMID: 20233745 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3383362 Tue, 16 Mar 2010 00:00:00 +0100 3383362 http://www.medworm.com/index.php?rid=3374826&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231297%26dopt%3DAbstract CONCLUSIONS: For CD5+ DLBCL, the addition of rituximab to chemotherapy significantly improved the PFS, but not OS. Therefore, it is thought that a new treatment strategy is necessary for CD5+ DLBCL. PMID: 20231297 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374826 Mon, 15 Mar 2010 00:00:00 +0100 3374826 http://www.medworm.com/index.php?rid=3374825&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231298%26dopt%3DAbstract CONCLUSIONS: Our data demonstrate the noninferiority of IP versus EP for survival in primarily Western patients with SCLC-ED. A meta-analysis is required to finally assess the role of irinotecan in this setting. PMID: 20231298 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374825 Mon, 15 Mar 2010 00:00:00 +0100 3374825 http://www.medworm.com/index.php?rid=3374824&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231299%26dopt%3DAbstract CONCLUSIONS: The addition of rituximab to salvage chemotherapy improves response rates and EFS in patients with relapsed DLBCL after ASCT. These patients may benefit from rituximab retreatment, although larger prospective studies are needed to confirm these results. PMID: 20231299 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374824 Mon, 15 Mar 2010 00:00:00 +0100 3374824 http://www.medworm.com/index.php?rid=3374823&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231300%26dopt%3DAbstract CONCLUSIONS: To resolve the issue in question, a meta-analysis of relevant studies is required, and new trials should be launched to explore new drug combinations against observation. Currently, delivery of adjuvant chemotherapy in patients undergoing preoperative radio(chemo)therapy is not evidence based. PMID: 20231300 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374823 Mon, 15 Mar 2010 00:00:00 +0100 3374823 http://www.medworm.com/index.php?rid=3374822&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231301%26dopt%3DAbstract CONCLUSION: In a population of men with a prevalence of depression similar to that of the normal population, almost none of those responding 'No' to the written question 'Are you depressed?' were depressed according to HADS-D >/=11. Adding the category 'I don't know' increases sensitivity in detecting depression. PMID: 20231301 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374822 Mon, 15 Mar 2010 00:00:00 +0100 3374822 http://www.medworm.com/index.php?rid=3374821&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231302%26dopt%3DAbstract Authors: Casula M, Budroni M, Cossu A, Ascierto PA, Mozzillo N, Canzanella S, Muggiano A, Palmieri G PMID: 20231302 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374821 Mon, 15 Mar 2010 00:00:00 +0100 3374821 http://www.medworm.com/index.php?rid=3374819&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231303%26dopt%3DAbstract CONCLUSION: Critical deletions represent a time-dependent prognostic factor limited to the first 4 years after surgery, which could help identify a subset with higher and earlier risk for relapse in GIST patients. PMID: 20231303 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374819 Mon, 15 Mar 2010 00:00:00 +0100 3374819 http://www.medworm.com/index.php?rid=3374817&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231304%26dopt%3DAbstract Authors: Sankaranarayanan R, Boffetta P The burden of cancer in low- and medium-income countries (LMIC) is expected to increase in the next decades. The application of current knowledge and results of research in key areas would contribute to limit the impact of this phenomenon. Opportunities for research on cancer prevention in LMIC include investigating specific circumstances of exposure to known carcinogens and to agents which are not prevalent in other regions, as well as interactions among carcinogens and between genetic and environmental factors. Early detection both by screening and early clinical diagnosis represents an important component of cancer control in LMIC. Research has been carried out to identify effective and sustainable approaches for early detection of cervical ca... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374817 Mon, 15 Mar 2010 00:00:00 +0100 3374817 http://www.medworm.com/index.php?rid=3374814&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20231305%26dopt%3DAbstract CONCLUSIONS: PNET of GCT origin is associated with an adverse outcome. For low-volume disease, surgery is the optimal initial therapy. CAV/IE may have a role in patients with unresectable disease. PMID: 20231305 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3374814 Mon, 15 Mar 2010 00:00:00 +0100 3374814 http://www.medworm.com/index.php?rid=3355337&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F03%252F10%252010.48%2522%255BMHDA%255D%253A%25222010%252F03%252F12%252007.42%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F03%252F10%252010.48%2522%255BEDAT%255D%29%29 58 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/03/12PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3355337 Fri, 12 Mar 2010 12:42:02 +0100 3355337 http://www.medworm.com/index.php?rid=3348369&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20211870%26dopt%3DAbstract CONCLUSIONS: Weekly PCb regimen was very active and tolerable as neoadjuvant treatment of breast cancer. This weekly PCb regimen should consider as a reasonable nonanthracycline-containing option in the neoadjuvant treatment of breast cancer. PMID: 20211870 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3348369 Mon, 08 Mar 2010 00:00:00 +0100 3348369 http://www.medworm.com/index.php?rid=3348368&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20211871%26dopt%3DAbstract CONCLUSIONS: There were significant associations especially for cardiac dysfunction with use of chemotherapy/radiation therapy and risks of developing cardiac toxicity in NSCLC patients. The risks of treatment-associated cardiac toxicity, specifically ischemic heart disease and cardiac dysfunction, were greatest among those with left-sided lung tumors. PMID: 20211871 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3348368 Mon, 08 Mar 2010 00:00:00 +0100 3348368 http://www.medworm.com/index.php?rid=3303486&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F02%252F23%252011.30%2522%255BMHDA%255D%253A%25222010%252F02%252F25%252008.20%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F02%252F23%252011.30%2522%255BEDAT%255D%29%29 39 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/02/25PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3303486 Thu, 25 Feb 2010 13:20:02 +0100 3303486 http://www.medworm.com/index.php?rid=3297684&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20172906%26dopt%3DAbstract CONCLUSIONS: Rituximab usage is an independent risk factor of DON. DON correlates with increased occurrence of infectious events. Careful follow-up would be needed after the onset of DON. PMID: 20172906 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3297684 Fri, 19 Feb 2010 00:00:00 +0100 3297684 http://www.medworm.com/index.php?rid=3292099&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20167595%26dopt%3DAbstract CONCLUSIONS: Vascular origin is an independent adverse prognostic factor for MFS and OS in patients with LMS. Patients with metastatic vLMS had a similar outcome than patients with metastatic LMS of other origin. PMID: 20167595 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3292099 Thu, 18 Feb 2010 00:00:00 +0100 3292099 http://www.medworm.com/index.php?rid=3288416&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20164149%26dopt%3DAbstract CONCLUSION: Low-dose induction chemotherapy can be given safely in selected individuals and does not adversely affect subsequent chemotherapy or outcome. PMID: 20164149 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3288416 Wed, 17 Feb 2010 00:00:00 +0100 3288416 http://www.medworm.com/index.php?rid=3288415&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20164150%26dopt%3DAbstract Conclusion(s): These findings point toward the role of p38 and Bax in the induction of apoptosis, which was confirmed by increase in caspase-3 activity. However, the increase in ERK1 expression with regard to leukocytosis could translate to a proliferative/differentiation effect. PMID: 20164150 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3288415 Wed, 17 Feb 2010 00:00:00 +0100 3288415 http://www.medworm.com/index.php?rid=3280514&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20157180%26dopt%3DAbstract CONCLUSION: Ocrelizumab demonstrated activity in patients with relapsed/refractory FL following prior rituximab treatment, with safety similar to rituximab although adverse events appeared milder. PMID: 20157180 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3280514 Mon, 15 Feb 2010 00:00:00 +0100 3280514 http://www.medworm.com/index.php?rid=3280521&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20154303%26dopt%3DAbstract CONCLUSION: In Xp11 translocation RCC, targeted therapy achieved objective responses and prolonged PFS similar to those reported for clear-cell RCC. PMID: 20154303 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3280521 Fri, 12 Feb 2010 00:00:00 +0100 3280521 http://www.medworm.com/index.php?rid=3280516&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20154304%26dopt%3DAbstract CONCLUSION: In the second largest cohort of low-risk GTN patients reported to date, choriocarcinoma pathology and CL(hCG) </=0.37 l/day were major independent predictive factors for MTX resistance risk. PMID: 20154304 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3280516 Fri, 12 Feb 2010 00:00:00 +0100 3280516 http://www.medworm.com/index.php?rid=3270200&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20150572%26dopt%3DAbstract CONCLUSIONS: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies. PMID: 20150572 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270200 Thu, 11 Feb 2010 00:00:00 +0100 3270200 http://www.medworm.com/index.php?rid=3270199&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20150573%26dopt%3DAbstract CONCLUSIONS: With inadequate data from randomized controlled trials at the moment, our report indicates that second-line chemotherapy is effective and beneficial in patients with good performance status, higher Hb level along with higher TTP under first-line therapy. PMID: 20150573 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270199 Thu, 11 Feb 2010 00:00:00 +0100 3270199 http://www.medworm.com/index.php?rid=3270205&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20147740%26dopt%3DAbstract Authors: Attal N, PMID: 20147740 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270205 Wed, 10 Feb 2010 00:00:00 +0100 3270205 http://www.medworm.com/index.php?rid=3270204&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20147741%26dopt%3DAbstract CONCLUSION: Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population. PMID: 20147741 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270204 Wed, 10 Feb 2010 00:00:00 +0100 3270204 http://www.medworm.com/index.php?rid=3270203&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20147742%26dopt%3DAbstract CONCLUSION: EpCAM+CK+CD45- that do not meet strict definitions for CTC are strong prognostic markers for survival. PMID: 20147742 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270203 Wed, 10 Feb 2010 00:00:00 +0100 3270203 http://www.medworm.com/index.php?rid=3270202&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20147743%26dopt%3DAbstract CONCLUSION: We provide the evidence that FGFR4 388Arg is an independent predictor of pCR following AC-Doc as NCT in PBC. PMID: 20147743 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270202 Wed, 10 Feb 2010 00:00:00 +0100 3270202 http://www.medworm.com/index.php?rid=3270201&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20147744%26dopt%3DAbstract CONCLUSIONS: RIT is an effective therapy in FL patients, as confirmed in our study too. Disease extension before treatment and response to RIT, as assessed by FDG-PET, result as main predictors of PFS, with the post-RIT PET result being the only independent predictive factor. PMID: 20147744 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3270201 Wed, 10 Feb 2010 00:00:00 +0100 3270201 http://www.medworm.com/index.php?rid=3263551&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20142409%26dopt%3DAbstract Authors: Chen ZG, Pan HX, Wang T, Cai LE, Lei YY, Su CH, Luo HH PMID: 20142409 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263551 Mon, 08 Feb 2010 00:00:00 +0100 3263551 http://www.medworm.com/index.php?rid=3263550&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20142410%26dopt%3DAbstract CONCLUSIONS: There was no statistical difference in relapse rate between one course of adjuvant CVB and surveillance for VASC- NSGCT patients. Two courses of adjuvant CVB for VASC+ NSGCT patients reduced the relapse rate with >90% in comparison to the surveillance group. Toxicity was unacceptably high for all patients receiving CVB. Adjuvant CVB chemotherapy has no place in the treatment of CS1 NSGCT. PMID: 20142410 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263550 Mon, 08 Feb 2010 00:00:00 +0100 3263550 http://www.medworm.com/index.php?rid=3263557&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20139151%26dopt%3DAbstract CONCLUSIONS: FDG-PET/CT detects recurrent DLBCL after first-line therapy with high PPV. However, it should not be used routinely and if only in selected high-risk patients to reduce radiation burden and costs. On the basis of our retrospective data, FDG-PET/CT during follow-up is indicated for patients <60 years with clinical signs of relapse and in patients >60 years with and without clinical signs of relapse. PMID: 20139151 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263557 Fri, 05 Feb 2010 00:00:00 +0100 3263557 http://www.medworm.com/index.php?rid=3263556&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20139152%26dopt%3DAbstract CONCLUSIONS: PORT significantly reduces LRF but has no effect on OS and DFS. However, due to poor patient accrual and older radiotherapy techniques in previous studies, there is a need for a new trial to evaluate PORT using conformal and intensity-modulated radiotherapy techniques. PMID: 20139152 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263556 Fri, 05 Feb 2010 00:00:00 +0100 3263556 http://www.medworm.com/index.php?rid=3263555&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20139153%26dopt%3DAbstract Authors: Gasent Blesa JM, Alberola Candel V, Giner Marco V, Giner-Bosch V, Provencio Pulla M, Laforga Canales JB PMID: 20139153 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263555 Fri, 05 Feb 2010 00:00:00 +0100 3263555 http://www.medworm.com/index.php?rid=3263554&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20139154%26dopt%3DAbstract CONCLUSIONS: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered. PMID: 20139154 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263554 Fri, 05 Feb 2010 00:00:00 +0100 3263554 http://www.medworm.com/index.php?rid=3263553&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20139155%26dopt%3DAbstract Authors: Kilickap S, Arslan C PMID: 20139155 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263553 Fri, 05 Feb 2010 00:00:00 +0100 3263553 http://www.medworm.com/index.php?rid=3263552&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20139156%26dopt%3DAbstract CONCLUSION: This national database reveals relevant information regarding epidemiology, current clinical practices and prognosis of NETs in Spain, providing valuable insights that may contribute to understand regional disparities in the incidence, patterns of care and survival of this heterogeneous disease across different continents and countries. PMID: 20139156 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3263552 Fri, 05 Feb 2010 00:00:00 +0100 3263552 http://www.medworm.com/index.php?rid=3247249&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20133382%26dopt%3DAbstract CONCLUSIONS: This review indicates the potential utility of proteasome inhibition for substantially enhancing activity of other therapeutic approaches. It explains the mechanisms responsible for the observed clinical activity of bortezomib-based regimens and elucidates novel therapeutic approaches through identification of combinations of agents with complimentary mechanisms of action. PMID: 20133382 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3247249 Thu, 04 Feb 2010 00:00:00 +0100 3247249 http://www.medworm.com/index.php?rid=3247248&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20133383%26dopt%3DAbstract CONCLUSIONS: Investigator-initiated trials have led to the discovery and development of innovative, safe, and effective cancer treatments. To ensure that such research continues, action will be required on the parts of legislative and regulatory bodies, industry, universities, patient advocacy organisations, and preclinical and clinical academic scientists. PMID: 20133383 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3247248 Thu, 04 Feb 2010 00:00:00 +0100 3247248 http://www.medworm.com/index.php?rid=3247251&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20129998%26dopt%3DAbstract CONCLUSION: High plasma D-dimer level on postoperative day 3, the use of rHuEPO, and non-O blood group were independent risk factors for postoperative VTE. PMID: 20129998 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3247251 Wed, 03 Feb 2010 00:00:00 +0100 3247251 http://www.medworm.com/index.php?rid=3247250&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20129999%26dopt%3DAbstract Authors: de Crevoisier R, Fizazi K PMID: 20129999 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3247250 Wed, 03 Feb 2010 00:00:00 +0100 3247250 http://www.medworm.com/index.php?rid=3240147&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20124350%26dopt%3DAbstract CONCLUSIONS: A calibrated six-panel assay of TAAs has been validated for identifying nearly 40% of primary lung cancers via a peripheral blood test. Levels of reproducibility, precision and linearity would be acceptable for an assay used in a regulated clinical setting. PMID: 20124350 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3240147 Tue, 02 Feb 2010 00:00:00 +0100 3240147 http://www.medworm.com/index.php?rid=3225205&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20110291%26dopt%3DAbstract Authors: Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J, PMID: 20110291 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3225205 Mon, 01 Feb 2010 00:00:00 +0100 3225205 http://www.medworm.com/index.php?rid=3225204&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20110292%26dopt%3DAbstract CONCLUSIONS: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response to erlotinib therapy. PMID: 20110292 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3225204 Mon, 01 Feb 2010 00:00:00 +0100 3225204 http://www.medworm.com/index.php?rid=3225206&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20110289%26dopt%3DAbstract CONCLUSION: Compared with a patient group with comparable characteristics treated with systemic chemotherapy, IHP does not provide a benefit in overall survival in patients with isolated nonresectable colorectal liver metastases. Currently, the use of IHP cannot be advocated outside the scope of clinical studies. PMID: 20110289 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3225206 Thu, 28 Jan 2010 00:00:00 +0100 3225206 http://www.medworm.com/index.php?rid=3206848&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F01%252F24%252013.22%2522%255BMHDA%255D%253A%25222010%252F01%252F26%252010.10%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F01%252F24%252013.22%2522%255BEDAT%255D%29%29 21 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/01/26PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3206848 Tue, 26 Jan 2010 15:10:02 +0100 3206848 http://www.medworm.com/index.php?rid=3201947&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20093351%26dopt%3DAbstract CONCLUSIONS: While limited by size, TRAFIC has long follow-up. No evidence of a clinically worthwhile benefit for the infusional treatment compared with standard treatment was observed which would justify further investigation or widespread use. PMID: 20093351 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3201947 Thu, 21 Jan 2010 00:00:00 +0100 3201947 http://www.medworm.com/index.php?rid=3201946&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20093352%26dopt%3DAbstract Authors: Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG PMID: 20093352 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3201946 Thu, 21 Jan 2010 00:00:00 +0100 3201946 http://www.medworm.com/index.php?rid=3198118&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089557%26dopt%3DAbstract CONCLUSION: With a FNR of 13.6%, we do not recommend SLNB as a routine procedure for MST, even for small tumor. PMID: 20089557 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198118 Wed, 20 Jan 2010 00:00:00 +0100 3198118 http://www.medworm.com/index.php?rid=3198117&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089558%26dopt%3DAbstract CONCLUSION: BMI < 25 kg/m(2) with diminished muscle mass is a significant predictor of toxicity in metastatic RCC patients treated with sorafenib. PMID: 20089558 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198117 Wed, 20 Jan 2010 00:00:00 +0100 3198117 http://www.medworm.com/index.php?rid=3198116&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089559%26dopt%3DAbstract CONCLUSION: Incidence of acute PN during CapOx appears similar to FOLFOX4 but chronic PN in adjuvant patients may be more common with CapOx. PMID: 20089559 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198116 Wed, 20 Jan 2010 00:00:00 +0100 3198116 http://www.medworm.com/index.php?rid=3198115&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089560%26dopt%3DAbstract CONCLUSION: A citrulline-based assessment score appears objective, validated, reproducible, reliable, specific and sensitive making it a suitable first choice for measuring and monitoring intestinal mucositis. PMID: 20089560 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198115 Wed, 20 Jan 2010 00:00:00 +0100 3198115 http://www.medworm.com/index.php?rid=3198114&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089561%26dopt%3DAbstract Authors: Mousavi SR, Akdari ME PMID: 20089561 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198114 Wed, 20 Jan 2010 00:00:00 +0100 3198114 http://www.medworm.com/index.php?rid=3198113&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089562%26dopt%3DAbstract CONCLUSION: In this randomised trial, no differences in the efficacy study end points were observed between the two treatment arms. PMID: 20089562 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198113 Wed, 20 Jan 2010 00:00:00 +0100 3198113 http://www.medworm.com/index.php?rid=3198112&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089563%26dopt%3DAbstract Authors: Mazza R, Lina M, Boffi R, Invernizzi G, De Marco C, Pierotti M A cancer patient who smokes is a very fragile person and we identify in scientific literature three main areas of clinical practice and research to develop the care of smokers with cancer. (i) Telling facts: smoking impacts on the survival and on the outcomes of surgery, chemo-, radio- and biological therapies. The aim of our intervention was to enable patients to make informed choices about smoking. (ii) Offering sensitive and effective smoking cessation like an instrument of patient empowerment to motivate change in smoker patient lifestyle. (iii) Assisting smoker patients if they develop acute nicotine withdrawal symptoms. Smoking care and nicotine replacement therapy can support temporary abstinence during the ... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198112 Wed, 20 Jan 2010 00:00:00 +0100 3198112 http://www.medworm.com/index.php?rid=3198111&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089564%26dopt%3DAbstract Authors: Perez-Garcia J, Morales R, Valverde CM, Rodon J, Suarez C, Semidey ME, Garcia-Patos V, Bartralot R, Serra M, Carles J PMID: 20089564 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198111 Wed, 20 Jan 2010 00:00:00 +0100 3198111 http://www.medworm.com/index.php?rid=3198110&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089565%26dopt%3DAbstract Authors: Liu YS PMID: 20089565 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198110 Wed, 20 Jan 2010 00:00:00 +0100 3198110 http://www.medworm.com/index.php?rid=3198109&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089566%26dopt%3DAbstract CONCLUSIONS: The OS and PFS of bevacizumab +/- erlotinib-treated patients with renal cell carcinoma were associated with changes in expression of protein and gene expression markers related to PI3K pathway and cell cycle signaling. PMID: 20089566 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198109 Wed, 20 Jan 2010 00:00:00 +0100 3198109 http://www.medworm.com/index.php?rid=3198108&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089567%26dopt%3DAbstract Conclusions: Sunitinib and sorafenib can be safely given to patients with renal insufficiency, provided adequate monitoring of renal function. For those patients developing an increase in Cr, dose modifications may be required to allow continuation of therapy. The clinical outcome of patients with baseline renal dysfunction and patients who develop renal dysfunction does not appear to be compromised. PMID: 20089567 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198108 Wed, 20 Jan 2010 00:00:00 +0100 3198108 http://www.medworm.com/index.php?rid=3198107&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20089568%26dopt%3DAbstract Authors: Pentheroudakis G, Pavlidis N PMID: 20089568 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3198107 Wed, 20 Jan 2010 00:00:00 +0100 3198107 http://www.medworm.com/index.php?rid=3189865&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20080829%26dopt%3DAbstract CONCLUSIONS: The response proportion to TMZ in the neoadjuvant setting was 16%, not different than in the metastatic setting. Responses were seen even in tumors with a methylated MGMT promoter. Pretreatment cryopreserved tumor adequate for microarray analysis could be obtained in most, but not all, patients. Post-treatment tumor was unavailable in complete responders. PMID: 20080829 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3189865 Fri, 15 Jan 2010 00:00:00 +0100 3189865 http://www.medworm.com/index.php?rid=3189864&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20080830%26dopt%3DAbstract CONCLUSION: In patients treated with a single injection of palonosetron on day 1, reducing dexamethasone is an option that is not associated with significant reduction in antiemetic control during the 5-day period or an impact on patient functioning. PMID: 20080830 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3189864 Fri, 15 Jan 2010 00:00:00 +0100 3189864 http://www.medworm.com/index.php?rid=3189863&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20080831%26dopt%3DAbstract Authors: Duffy SW, Greenberg DC, Chou P, Brown CH, Purushotham AD, Wishart GC PMID: 20080831 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3189863 Fri, 15 Jan 2010 00:00:00 +0100 3189863 http://www.medworm.com/index.php?rid=3189862&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20080832%26dopt%3DAbstract Authors: Okamura A, Wakahashi K, Ishii S, Katayama Y, Yamamoto K, Matsui T PMID: 20080832 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3189862 Fri, 15 Jan 2010 00:00:00 +0100 3189862 http://www.medworm.com/index.php?rid=3172865&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20067918%26dopt%3DAbstract CONCLUSIONS: There is a small but definite risk of major early CVE associated with chemotherapy of TGCC. Physicians caring for TGCC patients must be aware of this hazard. PMID: 20067918 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3172865 Tue, 12 Jan 2010 00:00:00 +0100 3172865 http://www.medworm.com/index.php?rid=3165340&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20064829%26dopt%3DAbstract CONCLUSION: Treatment with bevacizumab and TMZ is feasible and well tolerated but did not improve PFS6 and median OS. PMID: 20064829 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3165340 Mon, 11 Jan 2010 00:00:00 +0100 3165340 http://www.medworm.com/index.php?rid=3165339&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20064830%26dopt%3DAbstract CONCLUSION: Overexpression of AIB1 might provide a selective advantage for lymph node metastasis of lung ADC and serve as a useful biomarker for poor prognosis for NSCLC patients. PMID: 20064830 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3165339 Mon, 11 Jan 2010 00:00:00 +0100 3165339 http://www.medworm.com/index.php?rid=3165338&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20064831%26dopt%3DAbstract CONCLUSIONS: The consistency in evaluating eligibility of patients with central tumors for BVZ treatment is weak. The study group indicated more stringent criteria to help physicians in taking the best treatment choice that need however to be prospectively validated. PMID: 20064831 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3165338 Mon, 11 Jan 2010 00:00:00 +0100 3165338 http://www.medworm.com/index.php?rid=3165337&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20064832%26dopt%3DAbstract CONCLUSION: RR increment obtained by the addition of MTA to a standard therapy may be useful to predict survival benefit in clinical phase III trials of advanced cancer. PMID: 20064832 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3165337 Mon, 11 Jan 2010 00:00:00 +0100 3165337 http://www.medworm.com/index.php?rid=3156779&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222010%252F01%252F07%252019.36%2522%255BMHDA%255D%253A%25222010%252F01%252F09%252016.16%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222010%252F01%252F07%252019.36%2522%255BEDAT%255D%29%29 25 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2010/01/09PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3156779 Sat, 09 Jan 2010 21:16:02 +0100 3156779 http://www.medworm.com/index.php?rid=3149654&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20047974%26dopt%3DAbstract Authors: Auman JT, McLeod HL PMID: 20047974 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3149654 Mon, 04 Jan 2010 00:00:00 +0100 3149654 http://www.medworm.com/index.php?rid=3105860&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20019090%26dopt%3DAbstract CONCLUSIONS: PI is the most important prognostic factor in MCL. The cut-off of 30% is clinically meaningful and can be used to tailor the intensity of therapy in future clinical trials. PMID: 20019090 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3105860 Sun, 20 Dec 2009 11:42:05 +0100 3105860 http://www.medworm.com/index.php?rid=3105864&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20019086%26dopt%3DAbstract CONCLUSIONS: Even though the combination VC has similar effectiveness compared with DG in patients with metastatic lung cancer, it is associated with a lower overall treatment cost and hence, it is preferable from an economic perspective. However, it should be noted that although VC is associated with lower cost, it is also more toxic than DG regimen, a significant parameter that should be considered in clinical decisions. PMID: 20019086 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3105864 Thu, 17 Dec 2009 00:00:00 +0100 3105864 http://www.medworm.com/index.php?rid=3105863&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20019087%26dopt%3DAbstract CONCLUSION: The results of these studies demonstrate the biosimilarity of Zarzio(R) with its reference product Neupogen(R). PMID: 20019087 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3105863 Thu, 17 Dec 2009 00:00:00 +0100 3105863 http://www.medworm.com/index.php?rid=3105862&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20019088%26dopt%3DAbstract CONCLUSIONS: Poor PS and bone metastasis were identified as independent adverse prognostic factors in CUP. A simple prognostic model was developed and seems useful for decision making as to whether chemotherapy is indicated for CUP patients. PMID: 20019088 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3105862 Thu, 17 Dec 2009 00:00:00 +0100 3105862 http://www.medworm.com/index.php?rid=3105861&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D20019089%26dopt%3DAbstract CONCLUSIONS: Of the selective affected second tumors, it will be important to confirm the association of bladder cancer with nonseminoma treatment. PMID: 20019089 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3105861 Thu, 17 Dec 2009 00:00:00 +0100 3105861 http://www.medworm.com/index.php?rid=3093036&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222009%252F12%252F05%252010.40%2522%255BMHDA%255D%253A%25222009%252F12%252F16%252013.26%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222009%252F12%252F05%252010.40%2522%255BEDAT%255D%29%29 24 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2009/12/16PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3093036 Wed, 16 Dec 2009 18:26:02 +0100 3093036 http://www.medworm.com/index.php?rid=3059168&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19955334%26dopt%3DAbstract CONCLUSION: Both delayed and upfront therapy with ZOL for the prevention of AIBL and fractures in BC patients in the UK appear to result in highly acceptable cost-effectiveness ratios. PMID: 19955334 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3059168 Wed, 02 Dec 2009 00:00:00 +0100 3059168 http://www.medworm.com/index.php?rid=3059167&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19955335%26dopt%3DAbstract CONCLUSION: The 70-gene prognosis signature provides additional prognostic information especially in ER-positive lymph node-negative breast cancer patients with a predominant low or discordant clinical risk on the basis of AO, St G and/or NPI. PMID: 19955335 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3059167 Wed, 02 Dec 2009 00:00:00 +0100 3059167 http://www.medworm.com/index.php?rid=3059162&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19955336%26dopt%3DAbstract Authors: Pantano F, Santini D, Guida F, Vincenzi B, Tonini G PMID: 19955336 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3059162 Wed, 02 Dec 2009 00:00:00 +0100 3059162 http://www.medworm.com/index.php?rid=3034579&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19934250%26dopt%3DAbstract Authors: Basch E PMID: 19934250 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034579 Sat, 28 Nov 2009 06:00:38 +0100 3034579 http://www.medworm.com/index.php?rid=3034578&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940003%26dopt%3DAbstract Authors: Power DG, Feilchenfeldt J PMID: 19940003 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034578 Wed, 25 Nov 2009 00:00:00 +0100 3034578 http://www.medworm.com/index.php?rid=3034577&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940004%26dopt%3DAbstract CONCLUSION: Combination of gemcitabine and capecitabine is an active and safe regimen in anthracycline-pretreated breast cancer patients. PMID: 19940004 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034577 Wed, 25 Nov 2009 00:00:00 +0100 3034577 http://www.medworm.com/index.php?rid=3034576&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940005%26dopt%3DAbstract CONCLUSION: Our data provide evidence for a clinically relevant association between HER2/neu and VEGF-C expression in human breast cancer. Inhibiting HER2/neu may reduce tumor progression by blocking VEGF-C-mediated tumor cell proliferation and lymphogenic metastasis. PMID: 19940005 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034576 Wed, 25 Nov 2009 00:00:00 +0100 3034576 http://www.medworm.com/index.php?rid=3034575&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940006%26dopt%3DAbstract Authors: Gadner H PMID: 19940006 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034575 Wed, 25 Nov 2009 00:00:00 +0100 3034575 http://www.medworm.com/index.php?rid=3034574&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940007%26dopt%3DAbstract CONCLUSION: Cetuximab can be safely administered once every second week at doses between 400 and 700 mg/m(2), with 500 mg/m(2) being the most convenient and feasible dose for future studies. PMID: 19940007 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034574 Wed, 25 Nov 2009 00:00:00 +0100 3034574 http://www.medworm.com/index.php?rid=3034573&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940008%26dopt%3DAbstract Authors: Lord S, Hall PS, Seymour MT PMID: 19940008 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034573 Wed, 25 Nov 2009 00:00:00 +0100 3034573 http://www.medworm.com/index.php?rid=3034572&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940009%26dopt%3DAbstract Authors: Crivellari D, Molino A PMID: 19940009 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034572 Wed, 25 Nov 2009 00:00:00 +0100 3034572 http://www.medworm.com/index.php?rid=3034571&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940010%26dopt%3DAbstract Authors: Tariman JD, Berry DL, Cochrane B, Doorenbos A, Schepp K The preferred and actual participation roles during decision making have been studied over the past two decades; however, there is a lack of evidence on the degree of match between patients' preferred and actual participation roles during decision making. A systematic review was carried out to identify published studies that examined preferred and actual participation roles and the match between preferred and actual roles in decision making among patients with cancer. PubMed (1966 to January 2009), PsycINFO (1967 to January 2009), and CINAHL (1982 to January 2009) databases were searched to access relevant medical, psychological, and nursing literature. Twenty-two studies involving patients with breast, prostate, colorect... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034571 Wed, 25 Nov 2009 00:00:00 +0100 3034571 http://www.medworm.com/index.php?rid=3034570&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940011%26dopt%3DAbstract Authors: Surbone A PMID: 19940011 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034570 Wed, 25 Nov 2009 00:00:00 +0100 3034570 http://www.medworm.com/index.php?rid=3034569&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940012%26dopt%3DAbstract CONCLUSION: Axitinib is well tolerated in combination with FOLFOX, FOLFIRI, or FOLFOX plus 2 mg/kg bevacizumab. PK interactions appear to be absent. PMID: 19940012 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034569 Wed, 25 Nov 2009 00:00:00 +0100 3034569 http://www.medworm.com/index.php?rid=3034568&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940013%26dopt%3DAbstract Authors: Purushotham AD, Sullivan R 'Nothing in biology makes sense except in the light of evolution'! So said Theodore Dobzhansky. It is extraordinary how little Darwinism and post-Darwinian evolutionary science has penetrated medicine despite the fact that all biology is built upon its foundations. Randy Nesse, one of the fathers of Darwinian medicine, recently observed that doctors 'know the facts but not the origins'. Clearly, then, in this auspicious year-200 years since Charles Darwin's birth and 150 years since the first edition of the Origin of Species-it is time to reconsider Darwin's legacy to medicine and to invite evolution back into the biomedical fold. Here, we consider the legacy of Darwin and the contribution of the other great evolutionists such as Ernst Mayr to cancer... Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034568 Wed, 25 Nov 2009 00:00:00 +0100 3034568 http://www.medworm.com/index.php?rid=3034567&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19940014%26dopt%3DAbstract CONCLUSIONS: FBSF is an effective option for control of breakthrough pain in patients receiving ongoing opioid therapy. In this study, FBSF was well tolerated in the oral cavity, with no reports of treatment-related oral AEs. PMID: 19940014 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3034567 Wed, 25 Nov 2009 00:00:00 +0100 3034567 http://www.medworm.com/index.php?rid=3012940&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19920059%26dopt%3DAbstract Authors: Tassinari D, Drudi F, Lazzari-Agli L, Tombesi P, Sartori S PMID: 19920059 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3012940 Tue, 17 Nov 2009 00:00:00 +0100 3012940 http://www.medworm.com/index.php?rid=3012939&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19920060%26dopt%3DAbstract CONCLUSIONS: A new model on the basis of significant variables in the rituximab era and built on a large database of patients treated with rituximab is urgently needed. As prognostic models are changing with the efficacy and mechanisms of action of treatment utilized, looking for a new prognostic score is a never-ending story in which researchers are trying to hit a continuously moving target. PMID: 19920060 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3012939 Tue, 17 Nov 2009 00:00:00 +0100 3012939 http://www.medworm.com/index.php?rid=3004519&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19917571%26dopt%3DAbstract CONCLUSIONS: The regimen of docetaxel and PI-88 is active in CRPC but associated with significant haematologic toxicity. Further evaluation of different scheduling and dosing of PI-88 and docetaxel may be warranted to optimise efficacy with a more manageable safety profile. PMID: 19917571 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004519 Mon, 16 Nov 2009 00:00:00 +0100 3004519 http://www.medworm.com/index.php?rid=3004525&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914958%26dopt%3DAbstract CONCLUSION: The C5R protocol was feasible in the multicentric setting with favorable long-term survival in patients younger than 60 years. Despite dose adaptation, results in older patients were disappointing. PMID: 19914958 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004525 Fri, 13 Nov 2009 00:00:00 +0100 3004525 http://www.medworm.com/index.php?rid=3004524&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914959%26dopt%3DAbstract CONCLUSION: Single-agent oral vinorelbine is extremely safe in elderly patients with advanced NSCLC and ECOG PS of two or more and may represent a valid option in this very special population. PMID: 19914959 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004524 Fri, 13 Nov 2009 00:00:00 +0100 3004524 http://www.medworm.com/index.php?rid=3004523&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914960%26dopt%3DAbstract CONCLUSIONS: (18)F-FDG uptake, as measured by the SUV(max) before radiotherapy and metabolic response after radiotherapy, may predict the prognosis in locally advanced NPC. High (18)F-FDG uptake before and after radiotherapy may be useful for identifying patients requiring more aggressive treatment. PMID: 19914960 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004523 Fri, 13 Nov 2009 00:00:00 +0100 3004523 http://www.medworm.com/index.php?rid=3004522&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914961%26dopt%3DAbstract Authors: Glimelius B, Spindler KL, Frödin JE, Berglund A, Byström P, Qvortrup C, Jakobsen A, Pfeiffer P PMID: 19914961 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004522 Fri, 13 Nov 2009 00:00:00 +0100 3004522 http://www.medworm.com/index.php?rid=3004521&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914962%26dopt%3DAbstract CONCLUSIONS: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-betaRII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-betaRII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC. PMID: 19914962 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004521 Fri, 13 Nov 2009 00:00:00 +0100 3004521 http://www.medworm.com/index.php?rid=3004520&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19914963%26dopt%3DAbstract CONCLUSIONS: Asymptomatic patients without morphological residues and an early stage of disease do not need a routine FDG-PET/CT for follow-up. Asymptomatic patients with morphological residues should receive routine follow-up FDG-PET/CT for the first 24 months. Only patients with advanced initial stage do need a routine follow-up FDG-PET/CT beyond 24 months. PMID: 19914963 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=3004520 Fri, 13 Nov 2009 00:00:00 +0100 3004520 http://www.medworm.com/index.php?rid=2978746&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222009%252F11%252F07%252015.56%2522%255BMHDA%255D%253A%25222009%252F11%252F11%252008.56%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222009%252F11%252F07%252015.56%2522%255BEDAT%255D%29%29 34 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2009/11/11PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2978746 Wed, 11 Nov 2009 13:56:02 +0100 2978746 http://www.medworm.com/index.php?rid=2970574&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fsites%2Fentrez%3Fcmd%3DSearch%26db%3Dpubmed%26term%3D%28%28%28Ann%2520Oncol%29%2520AND%2520%25222009%252F11%252F05%252019.24%2522%255BMHDA%255D%253A%25222009%252F11%252F07%252015.56%2522%255BMHDA%255D%29%29%2520NOT%2520%28%28%2520%28%28%28%2522Ann%2520Oncol%2522%255BTIAB%255D%2520OR%2520%28%2522ann%2522%255BTIAB%255D%2520AND%2520%2522oncol%2522%255BTIAB%255D%29%2520OR%2520%2522ann%2520oncol%2522%255BTIAB%255D%29%29%29%2520AND%2520%25220001%2522%255BEDAT%255D%253A%25222009%252F11%252F05%252019.24%2522%255BEDAT%255D%29%29 26 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2009/11/07PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2970574 Sat, 07 Nov 2009 20:56:02 +0100 2970574 http://www.medworm.com/index.php?rid=2963713&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19884246%26dopt%3DAbstract CONCLUSIONS: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy. PMID: 19884246 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2963713 Mon, 02 Nov 2009 00:00:00 +0100 2963713 http://www.medworm.com/index.php?rid=2963712&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19884247%26dopt%3DAbstract Authors: Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA PMID: 19884247 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2963712 Mon, 02 Nov 2009 00:00:00 +0100 2963712 http://www.medworm.com/index.php?rid=2937016&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861581%26dopt%3DAbstract Authors: McMeekin DS PMID: 19861581 [PubMed - in process] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937016 Thu, 29 Oct 2009 14:58:05 +0100 2937016 http://www.medworm.com/index.php?rid=2937022&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861575%26dopt%3DAbstract CONCLUSION: The use of R-CHOP appears to reduce the overall risk of CNS relapse in patients with DLBCL particularly in patients who achieve a complete response. PMID: 19861575 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937022 Tue, 27 Oct 2009 00:00:00 +0100 2937022 http://www.medworm.com/index.php?rid=2937021&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861576%26dopt%3DAbstract CONCLUSIONS: AIs are active in MBC patients. This activity is correlated with a significant reduction in E(2) levels. Secondary resistance is in part related to a deleterious feedback loop resulting in a significant increase in substrate for aromatization. PMID: 19861576 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937021 Tue, 27 Oct 2009 00:00:00 +0100 2937021 http://www.medworm.com/index.php?rid=2937020&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861577%26dopt%3DAbstract CONCLUSIONS: The CTC count before and during treatment independently predicts PFS and OS in ACC patients treated with chemotherapy plus targeted agents and provides additional information to CT imaging. PMID: 19861577 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937020 Tue, 27 Oct 2009 00:00:00 +0100 2937020 http://www.medworm.com/index.php?rid=2937019&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861578%26dopt%3DAbstract CONCLUSIONS: MACOP-B regimen seems to be very active in the treatment of adult MS or SS-m LCH, with long-lasting responses in five of seven patients. PET scan merits further evaluation in the initial staging and in the evaluation of the response to chemotherapy. PMID: 19861578 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937019 Tue, 27 Oct 2009 00:00:00 +0100 2937019 http://www.medworm.com/index.php?rid=2937018&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861579%26dopt%3DAbstract CONCLUSIONS: Repeated resection after initial metastasectomy can be carried out safely and provides long-term survival in patients with recurrent pulmonary metastasis from colorectal cancer. Our findings indicate that close follow-up for the early detection of recurrence and parenchyma-saving resection can improve the results after repeated resection. PMID: 19861579 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937018 Tue, 27 Oct 2009 00:00:00 +0100 2937018 http://www.medworm.com/index.php?rid=2937017&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19861580%26dopt%3DAbstract CONCLUSIONS: Compared with patients with rising CEA, flare was an independent favourable predictive and prognostic factor for tumour response and survival. PMID: 19861580 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937017 Tue, 27 Oct 2009 00:00:00 +0100 2937017 http://www.medworm.com/index.php?rid=2937029&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858082%26dopt%3DAbstract Authors: Serrano C, Suárez C, Andreu J, Carles J PMID: 19858082 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937029 Sun, 25 Oct 2009 00:00:00 +0100 2937029 http://www.medworm.com/index.php?rid=2937028&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858083%26dopt%3DAbstract CONCLUSION: Although RP and RT/CCRT had similar therapeutic efficacy, the lower rate of late complications observed with RP makes it preferable to RT/CCRT. PMID: 19858083 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937028 Sun, 25 Oct 2009 00:00:00 +0100 2937028 http://www.medworm.com/index.php?rid=2937027&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858084%26dopt%3DAbstract CONCLUSIONS: Our observations expand the spectrum of HCV-associated lymphomas to include a subset of extranodal MZL characterized by a novel primary 'lipoma-like' subcutaneous presentation and indolent clinical course. PMID: 19858084 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937027 Sun, 25 Oct 2009 00:00:00 +0100 2937027 http://www.medworm.com/index.php?rid=2937026&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858085%26dopt%3DAbstract CONCLUSIONS: Homeopathic treatment is sought by cancer patients at a different phase during the course of the disease, which has particular implications for research. However, expectancies toward the benefit of the treatment as well as QoL data are similar. PMID: 19858085 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937026 Sun, 25 Oct 2009 00:00:00 +0100 2937026 http://www.medworm.com/index.php?rid=2937025&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858086%26dopt%3DAbstract CONCLUSIONS: This study has analyzed the most recent data from a European population in comparison with seven international studies. An increase, as postulated elsewhere, could not be confirmed. The incidence rate of STS in Austria ranges in the lower half of the international incidence rates (1.8-5.0 per 100 000 per year). Different inclusion criteria (Kaposi's sarcoma and dermatofibrosarcoma) and classifications in the various studies explain the increase of incidence in some studies rather than true increase of STS due to new or accumulated risk factors. PMID: 19858086 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937025 Sun, 25 Oct 2009 00:00:00 +0100 2937025 http://www.medworm.com/index.php?rid=2937024&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858087%26dopt%3DAbstract CONCLUSIONS: High ER and especially high PgR expression is a significant adverse prognostic indicator of DIN, and low-dose tamoxifen appears to be an active treatment. Women with low-expression ER or PgR DIN do not seem to benefit from tamoxifen. A definitive clinical trial is warranted. PMID: 19858087 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937024 Sun, 25 Oct 2009 00:00:00 +0100 2937024 http://www.medworm.com/index.php?rid=2937023&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19858088%26dopt%3DAbstract CONCLUSIONS: A significant number of patients show discordant quantitative expression of molecular markers between primary and nodal disease. Appropriately measured, lymph node receptor status could be a more accurate measurement for guiding adjuvant therapy, which requires testing in a clinical trial. PMID: 19858088 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2937023 Sun, 25 Oct 2009 00:00:00 +0100 2937023 http://www.medworm.com/index.php?rid=2931369&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19854721%26dopt%3DAbstract CONCLUSIONS: Bevacizumab-induced decrease in capillary density is reversible. Noninvasive assessment of capillary density during treatment with antiangiogenic drugs may be useful as a marker of treatment efficacy. PMID: 19854721 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2931369 Fri, 23 Oct 2009 00:00:00 +0100 2931369 http://www.medworm.com/index.php?rid=2931368&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19854722%26dopt%3DAbstract CONCLUSION: These data indicate that the sequential combination of XT followed by FEC is a well-tolerated, effective neoadjuvant treatment of stage II/III breast cancer. PMID: 19854722 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2931368 Fri, 23 Oct 2009 00:00:00 +0100 2931368 http://www.medworm.com/index.php?rid=2925095&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850635%26dopt%3DAbstract CONCLUSION: Polymorphism analysis of a simple blood sample is a feasible approach to biomarker analysis and the EGF61A>G polymorphism may influence the effect of first-line XELOX. Consequently, this marker deserves further investigation. PMID: 19850635 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925095 Thu, 22 Oct 2009 00:00:00 +0100 2925095 http://www.medworm.com/index.php?rid=2925094&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850636%26dopt%3DAbstract CONCLUSIONS: Despite extranodal NK/T-cell lymphoma frequently involves paranasal sinus, a routine CNS evaluation and prophylaxis do not seem to be necessary in NKPI group I or II patients due to a very low incidence. Nevertheless, CNS prophylaxis should be considered in NKPI groups III and IV. PMID: 19850636 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925094 Thu, 22 Oct 2009 00:00:00 +0100 2925094 http://www.medworm.com/index.php?rid=2925093&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850637%26dopt%3DAbstract CONCLUSIONS: In this subpopulation, sorafenib may reduce the occurrence of brain metastases. Antiangiogenic therapy, such as sorafenib, could be an effective preventive therapy for brain metastases in advanced RCC. PMID: 19850637 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925093 Thu, 22 Oct 2009 00:00:00 +0100 2925093 http://www.medworm.com/index.php?rid=2925092&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850638%26dopt%3DAbstract CONCLUSION: The current prognostic model successfully stratified patients with NK cell neoplasms with different outcomes. PMID: 19850638 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925092 Thu, 22 Oct 2009 00:00:00 +0100 2925092 http://www.medworm.com/index.php?rid=2925091&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850639%26dopt%3DAbstract CONCLUSIONS: Detection of >/=1 CTC/7.5 ml before neoadjuvant chemotherapy can accurately predict OS. Our findings may change the clinical management of nonmetastatic breast cancer and indicate that the metastatic efficiency of CTC could be higher than previously reported. PMID: 19850639 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925091 Thu, 22 Oct 2009 00:00:00 +0100 2925091 http://www.medworm.com/index.php?rid=2925090&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850640%26dopt%3DAbstract CONCLUSION: High DI doxorubicin based should be considered in patients with aggressive NHL. PMID: 19850640 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925090 Thu, 22 Oct 2009 00:00:00 +0100 2925090 http://www.medworm.com/index.php?rid=2925089&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850641%26dopt%3DAbstract CONCLUSION: Adult survivors of childhood cancer, especially those treated with cranial irradiation, are at increased risk of developing the metabolic syndrome. PMID: 19850641 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925089 Thu, 22 Oct 2009 00:00:00 +0100 2925089 http://www.medworm.com/index.php?rid=2925088&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850642%26dopt%3DAbstract CONCLUSION: This population-based study provides new insights into recent changes in the epidemiology of EN-MZL, mainly represented by the sharp reduced incidence of HP-positive g-MALT lymphomas. PMID: 19850642 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925088 Thu, 22 Oct 2009 00:00:00 +0100 2925088 http://www.medworm.com/index.php?rid=2925087&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19850643%26dopt%3DAbstract CONCLUSION: Further understanding of treatment resistance and interactions between bortezomib and docetaxel may provide novel approaches in managing HNSCC. PMID: 19850643 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2925087 Thu, 22 Oct 2009 00:00:00 +0100 2925087 http://www.medworm.com/index.php?rid=2920904&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19846467%26dopt%3DAbstract CONCLUSIONS: All six cases illustrate the wide spectrum of clinical presentation of lymphomas presenting primarily in the heart and emphasise that histology of all mass lesions is essential. Other series are small like ours highlighting the rarity of these tumours in the heart with the emphasis on imaging, early diagnosis and treatment. PMID: 19846467 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2920904 Tue, 20 Oct 2009 23:00:00 +0100 2920904 http://www.medworm.com/index.php?rid=2920903&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19846468%26dopt%3DAbstract CONCLUSIONS: GLMLE appears to be a well-tolerated compound in this setting. There appears to be no objective benefit. However, grade 3/4 hepatic toxicity noted in two patients is of concern and should be considered while evaluating patients taking GLMLE or while designing studies with this agent. PMID: 19846468 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2920903 Tue, 20 Oct 2009 23:00:00 +0100 2920903 http://www.medworm.com/index.php?rid=2913244&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19840953%26dopt%3DAbstract CONCLUSIONS: HER2-positive and triple-negative breast cancers have special predilection for metastases to the brain. Survival from brain metastases depended on performance status and the use of systemic treatment. PMID: 19840953 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2913244 Sun, 18 Oct 2009 23:00:00 +0100 2913244 http://www.medworm.com/index.php?rid=2902319&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19833817%26dopt%3DAbstract CONCLUSIONS: Local and regional recurrences after breast-conserving surgery are rare events. They are markers of tumor aggressiveness and indicators of an increased likelihood of distant metastases. PMID: 19833817 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2902319 Wed, 14 Oct 2009 23:00:00 +0100 2902319 http://www.medworm.com/index.php?rid=2902318&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19833818%26dopt%3DAbstract CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant treatment of stage III colon cancer patients. PMID: 19833818 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2902318 Wed, 14 Oct 2009 23:00:00 +0100 2902318 http://www.medworm.com/index.php?rid=2902317&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19833819%26dopt%3DAbstract CONCLUSIONS: Non-platinum and non-paclitaxel gemcitabine-containing doublets demonstrate similar overall survival and RR compared with the standard PC regimen. However, the treatment arms had distinct toxicity profiles. PMID: 19833819 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2902317 Wed, 14 Oct 2009 23:00:00 +0100 2902317 http://www.medworm.com/index.php?rid=2902316&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19833820%26dopt%3DAbstract CONCLUSION: Adjuvant ND reserved for patients with RD on PET-CT is the dominant and cost-effective strategy. PMID: 19833820 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2902316 Wed, 14 Oct 2009 23:00:00 +0100 2902316 http://www.medworm.com/index.php?rid=2902315&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19833821%26dopt%3DAbstract CONCLUSIONS: DOTATATE Y-90 therapy is effective and relatively safe in patients with GEP-NET. Standard doses of DOTATATE Y-90 result in a relatively low risk of myelotoxicity. However, due to ongoing risk of renal toxicity, careful monitoring of the kidney is recommended. PMID: 19833821 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2902315 Wed, 14 Oct 2009 23:00:00 +0100 2902315 http://www.medworm.com/index.php?rid=2899280&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19828559%26dopt%3DAbstract CONCLUSIONS: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause. PMID: 19828559 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899280 Tue, 13 Oct 2009 23:00:00 +0100 2899280 http://www.medworm.com/index.php?rid=2899279&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19828560%26dopt%3DAbstract CONCLUSIONS: Although most hospitalized cancer patients were at high risk, 40% did not receive any prophylaxis before the onset of acute VTE. There is a need to improve thromboprophylaxis in cancer patients, particularly in the presence of recent or ongoing chemotherapy. PMID: 19828560 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899279 Tue, 13 Oct 2009 23:00:00 +0100 2899279 http://www.medworm.com/index.php?rid=2899278&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19828561%26dopt%3DAbstract CONCLUSIONS: NSCLC histology significantly predicts efficacy outcomes for patients receiving pemetrexed. Several other factors are prognostic for the overall study population as well as a subset of patients with advanced nonsquamous NSCLC. PMID: 19828561 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899278 Tue, 13 Oct 2009 23:00:00 +0100 2899278 http://www.medworm.com/index.php?rid=2899277&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19828562%26dopt%3DAbstract CONCLUSION: S-1 combined with LV therapy demonstrated promising efficacy and acceptable safety in chemotherapy-naive patients with mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs. PMID: 19828562 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899277 Tue, 13 Oct 2009 23:00:00 +0100 2899277 http://www.medworm.com/index.php?rid=2899289&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19825879%26dopt%3DAbstract CONCLUSION: HPV is not associated with the recent surge in the incidence of biologically aggressive oral cavity cancer in young populations. PMID: 19825879 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899289 Mon, 12 Oct 2009 23:00:00 +0100 2899289 http://www.medworm.com/index.php?rid=2899288&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19825880%26dopt%3DAbstract CONCLUSIONS: The present results indicate that this schedule is a valid therapeutic approach in SMZL. Addition of rituximab significantly improved quality of response and consequently the outcome of the disease. PMID: 19825880 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899288 Mon, 12 Oct 2009 23:00:00 +0100 2899288 http://www.medworm.com/index.php?rid=2899287&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19825881%26dopt%3DAbstract CONCLUSION: HER2 overexpression was not associated with higher local or regional recurrence risk in subjects with pT(1-2)pN(0) breast cancer following mastectomy and nodal dissection after a median follow-up of >12 years. PMID: 19825881 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899287 Mon, 12 Oct 2009 23:00:00 +0100 2899287 http://www.medworm.com/index.php?rid=2899286&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19825882%26dopt%3DAbstract CONCLUSION: The 70-gene prognosis signature can accurately select postmenopausal patients at low risk of breast cancer-related death within 5 years of diagnosis and can be of clinical use in selecting postmenopausal women for adjuvant chemotherapy. PMID: 19825882 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899286 Mon, 12 Oct 2009 23:00:00 +0100 2899286 http://www.medworm.com/index.php?rid=2899285&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19825883%26dopt%3DAbstract CONCLUSION: In HL, JCV activation and chromosomal instability have been identified in PBL and associated with a poorer prognosis, especially in EBV+. PMID: 19825883 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899285 Mon, 12 Oct 2009 23:00:00 +0100 2899285 http://www.medworm.com/index.php?rid=2899284&cid=s_31094_6_f&fid=31094&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D19825884%26dopt%3DAbstract CONCLUSION: Our study confirms that substandard treatment increases considerably with age. Omission of radiotherapy had the greatest impact on OAS and DFS in the elderly population. PMID: 19825884 [PubMed - as supplied by publisher] (Source: Ann Oncol) Ann Oncol journals http://www.medworm.com/rss/comments.php?id=2899284 Mon, 12 Oct 2009 23:00:00 +0100 2899284